Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Bicara Therapeutics Appoints New Class Ii Directors

PUBLIC · BCAXJun 10, 2026•7 days ago

Position

Director

Company

Bicara Therapeutics

Jane Smith

CambridgeBiotechnologyHealth CareTherapeutics

Description

On June 9, 2026, Bicara Therapeutics Inc. held its annual meeting of stockholders. During the meeting, stockholders elected new individuals to serve as class II directors for a three-year term

Company Information

Company

Bicara Therapeutics

Location

Cambridge, Massachusetts, United States

About

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara’s lead product candidate, BCA101, is a first-in-class EGFR/TGF-β-trap bifunctional antibody currently being evaluated in a Phase 1/1b study. For more information, please visit www.bicara.com or follow us on LinkedIn or Twitter.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Bicara Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months